| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5506164 | Biochemical and Biophysical Research Communications | 2017 | 5 Pages |
•NOX-1 is a key mediator of inflammatory cytokine induced beta cell dysfunction.•Expression of NOX-1 protein results in beta cell dysfunction.•Deletion of NOX-1 protein confers protection to inflammatory cytokines.•Inhibition of NOX-1 is a candidate therapeutic target in diabetes.
Redox stress related loss of beta cell function is a feature of diabetes. Exposure of beta cells and islets to inflammatory mediators elevates reactive oxygen species (ROS) and beta cell dysfunction. Direct molecular manipulation of NADPH oxidase-1 (NOX-1) has identified a key role for NOX-1 in cytokine-induced beta cell dysfunction. Plasmid driven elevation of NOX-1 resulted in elevated ROS, loss of glucose-stimulated-insulin-secretion and increased apoptosis. These outcomes on beta cell function are analogous to cytokine treatment. In contrast, reduction of NOX-1 expression, by shRNA, conferred protection to beta cells and islets from the damaging effects of inflammatory cytokines. Collectively, these data support the therapeutic potential for NOX-1 inhibition in diabetes.
